Drugs that contain Sulfur Hexafluoride Lipid-type A Microspheres
1. Lumason patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(14 years from now) | |
| US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(14 years from now) | |
| US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION;INTRAVENOUS
More Information on Dosage
LUMASON family patents
